STAT3 and hepatocellular carcinoma: The combination treatment of sorafenib and ART exhibits a synergistic effect in inhibiting the growth of HCC cells, as well as in inducing apoptosis, and the mechanism is related to the inhibition of ART’s activation of the ERK and STAT3 signaling pathways by sorafenib [138].